Cogent Biosciences, Inc. Common Stock
COGTCogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for rare genetic diseases and cancers. The company's research centers on precision medicines that inhibit specific kinases involved in disease pathways, with a particular emphasis on conditions such as systemic mastocytosis and other tumor-related disorders. Founded to leverage insights into kinase biology, Cogent aims to deliver personalized treatment options for patients with limited or no effective therapies.
Company News
Cogent Biosciences announced positive clinical trial results for bezuclastinib, demonstrating significant improvements in symptoms and disease markers for patients with nonadvanced systemic mastocytosis, with plans to submit a New Drug Application in December 2025.
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) fell sharply in today’s pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first quarter 2024 financial results. Marinus Pharma report...
Related Companies
